RxDoctor Payments Data

Robert Rapp, MD

Internal Medicine · Havre de Grace, MDNPI 1720081003

Payments from drug & device makers

$188in general payments, 2019–2025

Across 10 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$81
  • AbbVie$48
  • GSK$26
  • Lilly USA, LLC$17
  • Johnson & Johnson$15

What the payments were for

  • Food & beverage$188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk5$81
AbbVie2$48
GSK1$26
Lilly USA, LLC1$17
Johnson & Johnson1$15

How this compares

$188 in reported general payments places this provider in the 50th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$276,138
Medicare patients
493
Services billed
4,771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban167$210,940
JardianceEmpagliflozin187$187,590
Avonex (4 Pack)Interferon Beta-1a12$104,795
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$83,336
OzempicSemaglutide54$78,270
XareltoRivaroxaban48$65,452
FarxigaDapagliflozin Propanediol41$51,558
CreonLipase/Protease/Amylase11$49,152
TrulicityDulaglutide34$44,716
EntrestoSacubitril/Valsartan21$22,281
Tresiba Flextouch U-200Insulin Degludec12$20,508
JanuviaSitagliptin Phosphate20$20,061
MyrbetriqMirabegron24$17,894
Repatha SureclickEvolocumab28$17,320
Combivent RespimatIpratropium/Albuterol Sulfate30$15,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix$26$93,216113 claims
Novo NordiskOzempic$81$78,27054 claims
Johnson & JohnsonXarelto$15$65,45248 claims
AbbVieCreon$48$49,15211 claims
Lilly USA, LLCTrulicity$17$44,71634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Havre de Grace

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →